secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001193125-24-252618
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA Q3: Revenue $7.2M, net loss $17.2M ($14M impairment); Twist 50% interest acquired
--------------------------------------------------------------------------------

- Total income/revenue of $7.2M in Q3 2024 vs $0.8M in Q3 2023; cash receipts $9.9M.
- Net loss of $17.2M vs $5.5M loss, driven by $14M non-cash impairment on Agenus royalty purchase agreement.
- Acquired 50% economic interest in Twist Bioscience's 60+ partnered early-stage programs for $15M.
- Cash and cash equivalents of $146.8M at Sept 30, 2024, down from $159.6M at Dec 31, 2023.
- Zevra's MIPLYFFA (arimoclomol) received FDA approval for Niemann-Pick disease type C, adding commercial royalty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524252618/0001193125-24-252618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524252618/d835519d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-252618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer